NeurochemistryDopamine D2 receptor upregulation in rat neostriatum following in vivo infusion of forskolinWanderoy, Maria H.1,2; Westlind-Danielsson, Anita1,3; Ahlenius, Sven1Author Information 1CNS Preclinical R&D, Astra Arcus AB, S-151 85 Södertälje, University of Stockholm, S-106 91 Stockholm, Sweden 2Department of Neurochemistry and Neurotoxicology, University of Stockholm, S-106 91 Stockholm, Sweden 3Corresponding Author: Anita Westlind-Danielsson ACKNOWLEDGEMENTS: For expert help with HPLC analysis we are indebted to Ms Ingrid Henriksson. Received 9 June 1997; accepted 14 July 1997 NeuroReport: September 8th, 1997 - Volume 8 - Issue 13 - p 2971-2976 Buy Abstract INTRACEREBROVENTRICULAR (i.c.v.) forskolin infusion for 5 days resulted in a concentration-dependent increase in rat striatal dopamine (DA) D2 receptors measured with [3H]raclopride. In animals given 50 nmol/h forskolin, the highest concentration used, raclopridemediated suppression of spontaneous locomotor activity was attenuated, and (±)-7-hydroxy-dipropyl-aminotetralin HBr (7-OH-DPAT)-mediated inhibition of striatal DA synthesis, as estimated by the accumulation of DOPA following inhibition of cerebral decarboxylase, was enhanced. These data suggest that the DA D2 receptor increase comprises receptors localized both postand presynaptically. The density of striatal DA D1 receptors was also changed with the forskolin treatment, in a concentration-dependent fashion, but in the opposite direction to DA D2 receptors. These findings suggest that striatal DA receptor sensitivity can be changed by manipulation at the second messenger level (e.g. independent of direct neurotransmitter—receptor interactions) in vivo. © Lippincott-Raven Publishers.